Dispensary Cannabidiol (CBD): Nothing to Worry About!

Child neurology open Pub Date : 2023-01-01 DOI:10.1177/2329048X231169395

Taylor Elliott, Andrew J Gienapp, James W Wheless

{"title":"Dispensary Cannabidiol (CBD): Nothing to Worry About!","authors":"Taylor Elliott, Andrew J Gienapp, James W Wheless","doi":"10.1177/2329048X231169395","DOIUrl":null,"url":null,"abstract":"Introduction: Despite US FDA approval of cannabidiol (CBD) liquid (Epidiolex®), patients with epilepsy still supplement prescription treatments with dispensary CBD. This study aimed to evaluate therapeutic effectiveness of dispensary CBD. Methods: We retrospectively collected dosage information, CBD serum levels, efficacy, and adverse effects from patient charts (children, adolescents, adults) (n = 18). Results: All 18 patients showed no clinical benefit from dispensary CBD as detectable serum levels never reached a therapeutic range of 150 ng/mL (6 patients had barely detectable levels that were below laboratory reporting thresholds). Minute levels of tetrahydrocannabinol (THC) were found in 3 patients, and moderate levels were found in 1 patient. Conclusion: Dispensary CBD failed to reach effective therapeutic levels in all of these patients. The presence of THC demonstrates the current lack of regulation of dispensary CBD. Anecdotal reports of clinical effectiveness should be considered an effect of concomitant prescription antiseizure medications and not dispensary CBD.","PeriodicalId":72572,"journal":{"name":"Child neurology open","volume":"10 ","pages":"2329048X231169395"},"PeriodicalIF":0.0000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/e2/f4/10.1177_2329048X231169395.PMC10123877.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Child neurology open","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/2329048X231169395","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Despite US FDA approval of cannabidiol (CBD) liquid (Epidiolex®), patients with epilepsy still supplement prescription treatments with dispensary CBD. This study aimed to evaluate therapeutic effectiveness of dispensary CBD. Methods: We retrospectively collected dosage information, CBD serum levels, efficacy, and adverse effects from patient charts (children, adolescents, adults) (n = 18). Results: All 18 patients showed no clinical benefit from dispensary CBD as detectable serum levels never reached a therapeutic range of 150 ng/mL (6 patients had barely detectable levels that were below laboratory reporting thresholds). Minute levels of tetrahydrocannabinol (THC) were found in 3 patients, and moderate levels were found in 1 patient. Conclusion: Dispensary CBD failed to reach effective therapeutic levels in all of these patients. The presence of THC demonstrates the current lack of regulation of dispensary CBD. Anecdotal reports of clinical effectiveness should be considered an effect of concomitant prescription antiseizure medications and not dispensary CBD.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

大麻二酚(CBD):不用担心!

导语:尽管美国FDA批准大麻二酚(CBD)液体(Epidiolex®)，癫痫患者仍然补充处方治疗药房CBD。本研究旨在评价药房CBD的治疗效果。方法:回顾性收集患者病历(儿童、青少年和成人)的剂量信息、CBD血清水平、疗效和不良反应(n = 18)。结果:所有18例患者均未显示药房CBD的临床益处，因为可检测的血清水平从未达到150 ng/mL的治疗范围(6例患者几乎未检测到低于实验室报告阈值的水平)。3例患者中发现微量四氢大麻酚(THC)， 1例患者中发现中度四氢大麻酚。结论:药房CBD在所有患者中均未达到有效治疗水平。四氢大麻酚的存在表明目前缺乏对药房CBD的监管。临床有效性的轶事报告应被认为是伴随处方抗癫痫药物的效果，而不是药房CBD。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Child neurology open

自引率

0.00%

发文量

审稿时长

15 weeks